Veterans and Servicemembers PTSD Emerging Treatment Review Act of 2026
Latest action: Referred to the House Committee on Armed Services. (2026-06-30)
View the official record →In plain English
What this bill does
This bill directs the Department of Defense to study and report to Congress on emerging investigational treatments for treatment-resistant PTSD in servicemembers, veterans, and those transitioning to civilian life. Specifically, within 180 days, the Assistant Secretary of Defense for Health Affairs would review safety, dosing, and feasibility data from a 2026 Arizona-sponsored clinical trial of whole-mushroom psilocybin for PTSD and assess its relevance to military populations. The bill only requires a report; it does not itself authorize or fund any treatment.
Who it affects
It would most affect active-duty servicemembers, National Guard and reserve members, veterans, and transitioning servicemembers who have PTSD that has not responded to existing treatments, as well as the federal agencies (DoD, VA, FDA, DEA, HHS) involved in producing or coordinating the report.
Key points
- Requires a single report to Congress within 180 days of enactment; does not by itself approve any new treatment or start any trial.
- The report must summarize safety, dosing, and adverse-event data from a specific 2026 Phase 1 psilocybin trial and analyze its applicability to military members.
- It must assess legal and regulatory requirements for accessing an investigational Schedule I substance, including coordination with the FDA and DEA and the federal Right to Try pathway.
- It must address continuity of care for members moving from military to VA health care, covering eligibility, oversight, informed consent, safety monitoring, and adverse-event reporting.
- It must estimate the resources, workforce, infrastructure, and timeline for possible pilot activities or expanded research starting in fiscal year 2027.
Plain-English summary generated by AI from the official record. Neutral by design; verify against the official text linked above.
Ask Versed about this bill
Versed reads the full bill and answers in plain English. Nonpartisan.
Ask anything about what this bill does, who it affects, or the case for and against it. Versed answers only from the bill text and tells you when something isn't in the bill.
Versed explains; it never tells you how to vote. Answers come from the bill text and may be incomplete. Verify against the official record.
Make your voice count
Email your representatives
Register where you stand in two clicks. We draft the note; you edit and send. Your position is tallied so reps can be held to account.
Be the first to tell your representatives where you stand on this.
1 · Your position
If you support this
Supporting the bill means requiring the Defense Department to produce and deliver a formal report to Congress reviewing emerging psilocybin-based PTSD treatment data and the legal steps for possible future research or access.
If you oppose this
Opposing the bill means choosing not to require this report, leaving any such Defense Department review of emerging PTSD treatments to happen only if initiated separately.
2 · How strongly
3 · Choose your representatives
Your address is used once to find your districts and is never stored.
Add your full address above to find the people who represent you.
4 · Your details
5 · Your message